Last updated: May 1, 2026
What does DK2191831 cover, and how does it sit in the Denmark drug patent landscape?
DK2191831 is a Denmark patent publication tied to a specific medicinal-ingredient and dosage-form scope through its claims, with enforceable coverage defined by (i) the active pharmaceutical substance (or a defined class of compounds), (ii) the claimed pharmaceutical compositions (including excipients and form), and (iii) the claimed method-of-treatment parameters (dose, patient population, regimen, or therapeutic use). The landscape around it is shaped by how those elements align to earlier European and WO filings and by whether DK2191831’s claims track the same inventive concept or add a narrower formulation and/or use layer.
Because claim-by-claim wording determines infringement scope and freedom-to-operate (FTO), the analysis below is structured to extract the claim “hooks” that drive (1) claim construction, (2) likely patent family reach, and (3) practical landscape intersections with competing developers in Denmark.
What is the technical and claim scope of DK2191831?
Claim architecture that typically governs enforceability
For Denmark medicinal patents, the effective claim scope usually falls into one of these patterns (often in combination in the same filing family):
- Product/composition claims
Coverage for a medicinal composition defined by ingredient(s) and composition/form constraints (e.g., salt form, polymorph, particle size, excipient composition, sustained-release matrix).
- Method-of-use claims
Coverage for treating a defined disease with the active ingredient/combination, using defined dosing or regimen parameters.
- Specific sub-genus claims
Narrower claim subsets that define a particular compound within a larger genus, or a particular patient subgroup or administration route.
What determines the “scope” in DK2191831
DK patent scope is defined by the actual claim language: the selection of limitations that are legally required to practice the invention. In practice, the enforceable reach in Denmark depends on whether DK2191831 claims:
- A specific compound or a salt/polymorph
Narrower scope to the defined form.
- A defined composition with formulation limitations
Narrower if excipient and delivery-system limits are claim elements.
- A defined therapeutic use with dosing/regimen limits
Narrower if dose or regimen is required in the claim.
Landscape consequences of each claim type
- If DK2191831 is composition-heavy (formulation and excipient limitations), generics can sometimes design around by using the same API but a different formulation pathway that falls outside the claimed excipient/delivery constraints.
- If DK2191831 is method-of-use-heavy (treatment, patient subset, dose/regimen), generic manufacturers typically focus on whether their labeling would infringe by using the same dosing regimen for the same indication.
- If DK2191831 includes both, it usually blocks multiple design-around strategies and raises licensing pressure, especially if the claims cover both “what” (composition) and “how” (treatment).
How does DK2191831 map to a broader patent family and European priority chain?
Family-level logic that shapes Denmark risk
Denmark drug enforceability is driven by what rights exist in DK for the same inventive disclosure. In most cases, DK2191831 aligns to an international (WO) or European (EP) priority chain. The landscape impact comes from:
- Whether DK2191831 claims are a translation of an EP/WO claim set or whether Denmark-spec claims were narrowed/changed.
- How many family members remain active in key EU jurisdictions (typically DE, FR, NL, SE, UK before it left the EU) and in EPO opposition windows.
- Whether claim narrowing occurred during prosecution or after oppositions; post-grant narrowing affects what DK2191831 can actually block.
Practical family mapping for investment and FTO
A DK filing like DK2191831 is typically assessed alongside:
- Closest WO publication and EP equivalents for claim consistency.
- Opposition history at EPO for the same family.
- National phase status in jurisdictions with high enforcement probability.
What does DK2191831 likely claim in infringement-critical terms?
Even when the patent’s title is generic, infringement-critical scope usually concentrates into claim limitations of the following types:
Composition limitations
- Active ingredient identity
Named compound or defined chemical entity class.
- Salt form / polymorph / hydrate / solvates
Salt identity is often decisive for generics.
- Release profile or delivery technology
Extended-release or delayed-release can create narrow design-space constraints.
- Excipients and ratios
If ratios are claimed, switching formulation can avoid infringement.
Method-of-treatment limitations
- Indication
Specific disease or condition is often required.
- Patient population
Subgroup limitations (e.g., biomarker-positive) narrow coverage.
- Dose and regimen
Exact dosing ranges or schedules can be decisive.
- Administration route
Oral vs. injection is often a necessary element.
Combination limitations
- Two-drug or multi-drug co-administration
Combination patents block only if all co-administration elements appear in the claim.
How does DK2191831 compare with other Denmark drug patents in the same therapeutic space?
Landscape drivers that cluster around a single DK patent
In a mature therapeutic area, Denmark often shows a stacked filing pattern:
- Early molecule protection (composition and use)
- Follow-on formulation patents (salt/polymorph, release profile)
- Treatment optimization (dose, duration, combination regimen)
- Patient selection (biomarkers, lines of therapy)
DK2191831 fits into one (or more) of these “stack” layers. The key for landscape positioning is whether it:
- Expands beyond the core molecule (e.g., new formulation tech or new dosing regimen)
- Narrows from earlier protection (e.g., a specific salt or specific patient subgroup)
- Duplicates the same concept as earlier family members (less landscape value for blocking beyond what the core already does)
Competitive impact pattern in Denmark
- If DK2191831 claims a specific formulation, it tends to create risk for generic manufacturers using alternate formulations even with the same API.
- If it claims a new indication/dose, it typically constrains label entry and sometimes delays market entry for biosimilar-like development paths (depending on product class and regulatory pathway).
- If it claims a combination regimen, it tends to be harder to design around without losing commercial viability.
What is the likely “freedom-to-operate” (FTO) decision tree around DK2191831?
For practical FTO in Denmark, the decision hinges on whether the product or planned regulatory label would meet all claim limitations. The typical FTO branching logic is:
-
Is your API the same entity (or defined salt/polymorph) as in DK2191831 claims?
- Yes: move to composition and use mapping
- No: likely low claim-coverage risk unless the claims define a broad genus
-
Does your product use the same formulation/delivery constraints?
- Yes: high risk for product infringement
- No: risk shifts to method-of-use claims
-
Does your intended label and regimen match the claimed method-of-treatment limitations?
- Yes: high risk for method infringement
- No: possible design-around, but only if the label avoids all required regimen elements
-
Is DK2191831 part of a stacked family where other claims cover your “escape routes”?
- Yes: high licensing pressure
- No: a narrow product/formulation change may clear risk
Where are the highest-stakes landscape intersections (regulatory and competitive)?
Intersections that drive litigation and licensing
- Patent families with both EP and DK coverage: higher enforcement probability.
- Claims that survive opposition: stronger blocking power.
- Claims tied to dosing regimens that appear in SmPC/labeling: higher likelihood of label-driven infringement.
- Claims tied to specific API forms: higher likelihood that generics must match an exact form.
Denmark-specific commercial consequences
Denmark decisions often translate into:
- Settlement leverage for incumbents (if claim limitations match labeling and marketed formulation).
- Entry timing risk for generics and biosimilars (if any claim path overlaps with intended product details).
- Narrow formulation strategy (if composition claims are controlling).
- Label strategy (if method claims are controlling).
Key Takeaways
- DK2191831’s legal scope is determined by claim limitations tied to (1) API identity/form, (2) composition/formulation constraints, and (3) method-of-treatment parameters such as indication and dosing regimen.
- The landscape impact in Denmark depends on whether DK2191831 is a molecule-core claim, a follow-on formulation claim, an indication/dose refinement, or a combination regimen claim.
- In FTO, the highest-stakes risk comes from whether a planned product or label meets all claim elements, not from the patent title or general field of use.
- The most actionable landscape work aligns DK2191831 with its family members (WO/EP equivalents) and maps opposition/prosecution narrowing to current enforceable claim scope.
- The design-around strategy is typically formulation-driven or label/regimen-driven depending on whether DK2191831 is composition- or method-heavy.
FAQs
1) What makes DK2191831 enforceable in Denmark?
Enforceability flows from the specific, legally required limitations in its granted/validated claims in Denmark, which typically bind on API identity (including salt/polymorph), composition/formulation constraints, and any claimed therapeutic regimen elements.
2) How do formulation claims differ from method-of-use claims in an FTO assessment?
Formulation claims require matching the claimed composition/form constraints, while method-of-use claims require matching the claimed treatment and regimen elements in the intended clinical use or labeling context.
3) Can a generic avoid DK2191831 by switching formulation while keeping the same API?
Yes if DK2191831 coverage is driven by composition-formulation limitations and the alternative formulation avoids those claimed excipient/delivery constraints. If method-of-use claims also match the intended label regimen, formulation changes alone may not clear risk.
4) Why does patent family mapping matter for a DK patent like DK2191831?
Because the enforceable scope in Denmark is shaped by what the family disclosed and what claim versions survived prosecution or opposition in the same inventive concept. Family members often indicate where claim narrowing did or did not occur.
5) What is the fastest way to identify whether DK2191831 blocks market entry?
Match the intended product and label to each claim limitation in sequence: API form, composition/formulation constraints, and finally indication and dosing/regimen elements. If any required element is missed, infringement risk drops along that claim path.
References (APA)
[1] European Patent Office. (n.d.). EPO register and publication database. https://www.epo.org/searching.html
